is semaglutide being banned Weight Loss Wednesday: Low-cost weight loss drug in La FDA announces ban for compounded

Adding obesity medication coverage increases annual premiums by approximately $150$300 per employee according to 2025 actuarial estimates from Tennessee benefits consultants

These therapies require a prescription and medical guidance

Clients who lose weight while protecting muscle and skin, supporting their metabolism, and staying accountable through weekly check-ins are significantly more likely to maintain their results

A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder

That loop matters because a plan only stays useful when it survives real life

[Abstract]2022 Jul;24(7):1255-1266